OTCMKTS:POLXF Polydex Pharmaceuticals (POLXF) Stock Price, News & Analysis $1.99 +0.01 (+0.30%) As of 08/7/2023 Add Compare Share Share Stock Analysis Stock Analysis About Polydex Pharmaceuticals Stock (OTCMKTS:POLXF) Get POLXF alerts:Sign Up Key Stats Today's Range$1.99▼$1.9950-Day Range$1.99▼$1.9952-Week Range$0.55▼$2.01Volume2,000 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Polydex Pharmaceuticals Limited is a Canadian pharmaceutical company engaged in the development, manufacture and marketing of pharmaceutical products. The company’s operations have included products for both human and veterinary applications, with activities spanning pharmaceutical ingredients and finished dosage products. Its product portfolio has included medicines and pharmaceutical chemicals used in areas such as anti-infective, antiseptic, analgesic, anesthetic and antihistamine treatments. Polydex has served customers in Canada and international markets through its pharmaceutical operations and product distribution activities. Publicly available information about the company’s current leadership, product portfolio and geographic reach is limited. Accordingly, specific details about its present operations and management are not included here.AI Generated. May Contain Errors. Read More Receive POLXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Polydex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. POLXF Stock News HeadlinesPolydex Pharmaceuticals (OTCMKTS:POLXF) Shares Pass Below 200 Day Moving Average - Time to Sell?September 24, 2026 | americanbankingnews.comPolydex Pharmaceuticals Limited Shareholders Vote to Approve BioSpectra Inc. Business CombinationJuly 18, 2023 | finance.yahoo.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.September 28 at 1:00 AM | Paradigm Press (Ad)Polydex Pharmaceuticals Limited: Polydex Pharmaceuticals Issues First Quarter Financial ResultsJune 15, 2023 | finanznachrichten.dePolydex Pharmaceuticals Limited and BioSpectra Inc. Announce Business CombinationApril 27, 2023 | finance.yahoo.comPolydex Pharmaceuticals Ltd.April 17, 2023 | barrons.comPolydex Pharmaceuticals GAAP EPS of -$0.09, revenue of $1.09MSeptember 17, 2022 | seekingalpha.comGlobal Computed Tomography (CT) Scanner Market to Reach $9.38 Billion by 2028 | Demand for AI based CT Scanner is On the RiseSeptember 16, 2022 | nz.finance.yahoo.comSee More Headlines POLXF Stock Analysis - Frequently Asked Questions How have POLXF shares performed this year? Polydex Pharmaceuticals' stock was trading at $1.9860 at the beginning of the year. Since then, POLXF stock has increased by 0.0% and is now trading at $1.9860. How do I buy shares of Polydex Pharmaceuticals? Shares of POLXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/28/2026Fiscal Year End1/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:POLXF CIK317158 Webwww.polydex.com Phone(416) 755-2231FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:POLXF) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our Partners"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Polydex Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Polydex Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
